BNP Paribas Financial Markets
TRVI icon

BNP Paribas Financial Markets’s Trevi Therapeutics TRVI Stock Holding History

BNP Paribas Financial Markets’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$372K Sell
19,930
-3,095
-13% -$45K ﹤0.01% 3915
2026
Q1 		$275K Buy
23,025
+969
+4% +$10.8K ﹤0.01% 3904
2025
Q4 		$276K Buy
22,056
+3,844
+21% +$44.4K ﹤0.01% 3906
2025
Q3 		$167K Sell
18,212
-12,784
-41% -$95.9K ﹤0.01% 4092
2025
Q2 		$170K Buy
30,996
+25,426
+456% +$158K ﹤0.01% 3836
2025
Q1 		$35K Sell
5,570
-2,116
-28% -$10.1K ﹤0.01% 4397
2024
Q4 		$31.7K Sell
7,686
-4,244
-36% -$13.6K ﹤0.01% 4588
2024
Q3 		$39.8K Buy
11,930
+6,764
+131% +$20.1K ﹤0.01% 3658
2024
Q2 		$15.4K Sell
5,166
-15,411
-75% -$42.8K ﹤0.01% 3674
2024
Q1 		$71K Sell
20,577
-111,632
-84% -$249K ﹤0.01% 3514
2023
Q4 		$177K Buy
132,209
+122,543
+1,268% +$186K ﹤0.01% 3258
2023
Q3 		$21.1K Sell
9,666
-1,183
-11% -$2.67K ﹤0.01% 3559
2023
Q2 		$25.9K Buy
+10,849
New +$27.3K ﹤0.01% 3568

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Frazier Life Sciences Management
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Woodline Partners
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

BNP Paribas Financial Markets's TRVI Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its Trevi Therapeutics (TRVI) stake by 13% in Q2 2026, selling an estimated $45K and leaving 19,930 shares worth $372K. The position accounts for ﹤0.01% of the portfolio, ranked #3915.

BNP Paribas Financial Markets first reported a position in TRVI in Q2 2023 and has held it in 13 quarters since. 218 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • BNP Paribas Financial Markets held 19,930 shares of Trevi Therapeutics worth $372K as of Q2 2026.
  • BNP Paribas Financial Markets sold 3,095 Trevi Therapeutics shares in Q2 2026, an estimated $45K.
  • Trevi Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #3915 holding.
  • BNP Paribas Financial Markets first reported a position in Trevi Therapeutics in Q2 2023 and has held it in 13 quarters since.
  • 218 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.